LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Low-Cost Blood Test May Enable Screening for Increased Bleeding Risk After Injury

By LabMedica International staff writers
Posted on 11 Oct 2015
From a proof-of-concept, pre-validation study, researchers have concluded that the admission hematocrit (AH) would likely provide a reliable predictor of increased bleeding risk in pediatric trauma patients.

From their retrospective review of approximately 1,340 trauma patients, ages 0 to 17 years, researchers from the Trauma Program at Children's Hospital Los Angeles (CHLA; Los Angeles, CA, USA) have suggested that an AH could be widely implemented to identify patients who may need intervention and thus improve the course and outcome of their trauma resuscitation.

Adult trauma studies have shown that a drop in hematocrit (test for percentage of the volume of whole blood that is made up of red blood cells) can occur immediately after injury – predicting ongoing occult blood loss. To date, the use of hematocrit in triaging bleeding pediatric trauma patients had not been investigated. In examining medical records of all patients who presented to CHLA’s level-1 pediatric trauma center between 2005 and 2013, the researchers found that an AH of 35-or-less was able to identify children requiring intervention (blood transfusion, angioembolization, or operation) for bleeding, up to 67 hours after arrival.

The results showed a significant difference in AH between patients who subsequently required a transfusion and those who did not. The cutoff figure of 35-or-less had a 94% sensitivity, 77% specificity, and 99.9% negative predictive value, indicating that use of this cutoff provides a reliable screening tool.

Unintentional injury from trauma is the leading cause of death in children over one year of age. Clinical assessment of young children can be far more challenging than adults, identifying their injuries (especially intra-abdominal) and assessing blood loss in children often requires additional resources and expense. "A quick and cost-effective measure, such as AH, to identify pediatric patients who are at a high risk for bleeding could provide a critical improvement in optimizing care for children, while reducing costs," said principal investigator Christopher P. Gayer, MD, PhD, FAAP, FACS, of Trauma Attending, Division of Pediatric Surgery, CHLA.

"AH can be done rapidly in the trauma bay, is relatively inexpensive, causes minimal harm, and can aid in critical decision-making and rapid identification of occult bleeding. Our results show that a hematocrit level of less than 35% on admission predicts a greater likelihood for the need of transfusion in pediatric blunt trauma patients," said first author Jamie Golden, MD, research fellow, CHLA.

The physicians noted that while a doctor's concern in the face of clinical signs of hemorrhagic shock should always take priority over lab data, a repeat hematocrit can be quickly performed if clinically indicated. They added that their study results, conducted retrospectively at a single site, require validation in a prospective, multicenter study.

The study, by Golden J et al, was published in the October, 2015, issue of the Journal of Trauma and Acute Care Surgery.

Related Links:

Children's Hospital Los Angeles


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Clinical Chemistry System
P780

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more